Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 6991 AL 7005

Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?

Saxena U.

Expert Opin Ther Targets. 2010 Dec;14(12):1273-7. doi: 10.1517/14728222.2010.528285.

Reliability and validity of the Norwegian version of the Brief Agitation Rating Scale (BARS) in dementia

Sommer OH, Engedal K.

Aging Ment Health. 2011 Mar;15(2):252-8. doi: 10.1080/13607863.2010.519318. Epub 2010 Dec 6.

Factors of error and effort in memory intervention for patients with Alzheimer's disease and amnesic syndrome

Mimura M, Komatsu S.

Psychogeriatrics. 2010 Dec;10(4):179-86. doi: 10.1111/j.1479-8301.2010.00339.x.

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

Devanand DP, Pelton GH, Cunqueiro K, Sackeim HA, Marder K.

Int J Geriatr Psychiatry. 2011 Sep;26(9):937-43. doi: 10.1002/gps.2630. Epub 2010 Dec 28.

NEP-like endopeptidases and Alzheimer's disease [corrected]

Marr RA, Spencer BJ.

Curr Alzheimer Res. 2010 May;7(3):223-9. doi: 10.2174/156720510791050849.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials

Siemers E, DeMattos RB, May PC, Dean RA.

Biomark Med. 2010 Feb;4(1):81-9. doi: 10.2217/bmm.09.85.

Biochemical markers in Alzheimer's disease clinical trials

Zetterberg H, Mattsson N, Shaw LM, Blennow K.

Biomark Med. 2010 Feb;4(1):91-8. doi: 10.2217/bmm.09.80.

Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease

Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, Sancarlo D, Vendemiale G, Pilotto A, Panza F.

Ageing Res Rev. 2010 Oct;9(4):399-417. doi: 10.1016/j.arr.2010.04.007. Epub 2010 May 2.

Integrating ADNI results into Alzheimer's disease drug development programs

Cummings JL.

Neurobiol Aging. 2010 Aug;31(8):1481-92. doi: 10.1016/j.neurobiolaging.2010.03.016. Epub 2010 May 5.

Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers

Serrano-Pozo A, Vega GL, Lütjohann D, Locascio JJ, Tennis MK, Deng A, Atri A, Hyman BT, Irizarry MC, Growdon JH.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):220-6. doi: 10.1097/WAD.0b013e3181d61fea.

What's next?

Coleman PD.

Neurobiol Aging. 2010 Aug;31(8):1493. doi: 10.1016/j.neurobiolaging.2010.05.005. Epub 2010 Jun 11.

Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment

Lorenzi M, Donohue M, Paternicò D, Scarpazza C, Ostrowitzki S, Blin O, Irving E, Frisoni GB; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1443-51, 1451.e1. doi: 10.1016/j.neurobiolaging.2010.04.036. Epub 2010 Jun 11.

Magnetic resonance imaging of Alzheimer's disease: from diagnosis to therapeutic evaluation

Gu XM, Jiang ZF, Huang HC.

Chin J Integr Med. 2010 Jun;16(3):276-82. doi: 10.1007/s11655-010-0276-8. Epub 2010 Aug 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias